TCR Engineered Donor T-Cells

A Controlled Multi-Arm Ph1 Study Evaluating the Safety and Feasibility of TCR Engineered Donor TCells Targeting HA1 (TSC-100) or HA2 (TSC-101) in HLA-A0201 Positive Patients Undergoing Haploidentical Allogeneic Stem Cell Transplantation

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
63 patients (estimated)
Sponsors
TScan Therapeutics, Inc.
Tags
Adoptive Cellular Therapy, T Cell (Allogeneic), Post-Allogeneic Stem Cell Transplant
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
1606
NCT Identifier
NCT05473910

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.